CrossRef 5. Sun B, Halmos G, Schally AV, et al.: Presence of receptors for bombesin/gastrin releasing peptide and mRNA for three receptors subtypes in human prostate cancer. Prostate 2000, 42: 295–303.PubMedCrossRef 6. Berruti A, Mosca A, Tucci M, et al.: Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone refractory disease. Endocr Relat Cancer 2005, 12: 109–17.PubMedCrossRef 7. Kadmon D, Thomson TC, Lynch GR, et al.: Elevated plasma chromogranin A concentrations in prostatic carcinoma. J Urol 1991, 146: 358–361.PubMed 8. Ischia R, Hobisch A, Bauer R, et al.: Elevated

levels of serum secretoneurin AZD6738 chemical structure in patients with therapy resistant carcinoma of prostate. J Urol 2000, 163: 1161–1165.PubMedCrossRef 9. Ferrero-Pous M, AZD4547 in vitro Hersant AM, Pecking A, et al.: Serum chromogranin A in advanced prostate cancer. Br J Urol Int 2001, 88: 790–6. 10. Sciarpa A, Voria G, Monti S, et al.: Clinical understaging in patients with 4SC-202 cost prostate adenocarcinoma submitted to radical prostatectomy: predictive value of serum Chromogranin A. Prostate 2004, 58: 421–428.CrossRef 11. Ahlegren G, Pedersen K, Lundberg S, et al.: Neuroendocrine differentiation is not prognostic

of failure after radical prostatectomy but correlates with tumor volume. Urology 2000, 56: 1011–1015.PubMedCrossRef 12. Sobin LH, Wittekind Ch (Eds): TNM classification of malignant tumors In 6th edition. 2002. 13. Gleason DF: Histologic grade, clinical stage, and patient age in prostate cancer. NCI Monogr 1988, 15–8. 14. Ferrero-Poüs M, Hersant AM, Pecking A, et al.: Serum chromogranin-A in advanced prostate cancer. BJU Int 2001, 88: 790–6.PubMedCrossRef 15. Sciarra A: Neuroendocrine differentiation in prostate adenocarcinoma. Eur Urol 2007, 52: 1373.PubMed 16. Angelsen A, Syversen U, Haugen OA, et al.: Neuroendocrine

differentiation in carcinomas of prostate: do neuroendocrine serum markers reflect immunohistochemical findings? Prostate 1997, 30: 1–6.PubMedCrossRef 17. Xing N, Qian J, Bostwick D, et al.: Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin. Prostate 2001, 48: 7–15.PubMedCrossRef 18. Shimizu S, Kumagai J, Eishi Y, et al.: Frequency and number of neuroendocrine tumor cells in prostate cancer: no difference between radical prostatectomy specimens from patients with and without neoadjuvant hormonal therapy. Baf-A1 price Prostate 2007, 67: 645–52.PubMedCrossRef 19. Fixemer T, Remberger K, Bonkhoff H: Apoptosis resistance of neuroendocrine phenotypes in prostatic adenocarcinoma. Prostate 2002, 53: 118–23.PubMedCrossRef 20. Tannock IF, Osoba D, Stockler MR, et al.: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996, 14: 1756–64.PubMed 21. Cussenot O, Villette JM, Valeri A, et al.: Plasma neuroendocrine markers in patients with benign prostatic hypertrophy and prostate carcinoma.